On April 10, the University of Missouri (MU) took its first formal step toward building NextGen MURR when school officials issued the request for qualifications for the project. The RFQ is a solicitation for interested companies to offer the design, engineering, licensing, environmental, and developmental services that are needed for NextGen MURR, planned to be larger and more capable than the school’s existing University of Missouri Research Reactor (MURR)—which itself has been the most powerful research reactor and most intense neutron source on any U.S. campus since it began operating in 1966.

BWXT Medical has submitted a new drug application to the U.S. Food and Drug Administration to request approval of its technetium-99m generator for medical imaging. A daughter isotope of molybdenum-99, Tc-99m is used in more than 40 million diagnostic procedures annually. BWXT Medical is a subsidiary of Lynchburg, Va.-based BWX Technologies.